ProCE Banner Activity

Germline BRCA Testing and Targeting With Adjuvant Olaparib in HER2- EBC

Slideset Download
Downloadable slideset describing germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.

Released: May 17, 2022

Expiration: May 16, 2023

Share

Faculty

Yara Abdou

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Yara Abdou, MD

Assistant Professor
Division of Medical Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina